AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLINUVEL PHARMACEUTICALS LTD

9.600

+0.1301.37%

Volume:36.90K

Turnover:354.58K

Market Cap:481.93M

PE:14.91

High:9.900

Open:9.660

Low:9.420

Close:9.470

52wk High:13.933

52wk Low:9.310

Shares:50.20M

Float Shares:41.32M

Volume Ratio:2.75

T/O Rate:0.09%

Dividend:0.05

Dividend Rate:0.52%

EPS(TTM):0.644

EPS(LYR):0.718

ROE:13.96%

ROA:10.62%

PB:1.94

PE(LYR):13.37

Loading ...

Overview Company News Filings

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

Clinuvel Pharmaceuticals Retains Philippe Wolgen as CEO

MT Newswires Live

Clinuvel Pharmaceuticals Ltd-Chair Letter to Shareholders

THOMSON REUTERS

Clinuvel Pharmaceuticals - We Expect That Nasdaq Listing for a Level Ii Adr May Be Possible in the First Half of This Year

THOMSON REUTERS

Clinuvel Pharmaceuticals Ltd - Philippe Wolgen to Continue as CEO

THOMSON REUTERS

Morgans says these small-cap ASX shares could rise 30% to 80%

A Look At Clinuvel Pharmaceuticals (ASX:CUV) Valuation After Softer Half Year Earnings Results

Simply Wall St.

Clinuvel Pharmaceuticals announces investor webinar release for the six months ended 31 December 2025

Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says

MT Newswires Live

Assessing Clinuvel Pharmaceuticals (ASX:CUV) Valuation After EMA SCENESSE Approval And Half Year Earnings

Simply Wall St.

BUZZ-Australia's Clinuvel Pharma at near 9-month low; Jefferies trims PT on slower sales

Clinuvel H1 net profit after tax AUD 10.4 million -26%

BRIEF-Clinuvel Pharmaceuticals Posts HY Net Profit After Tax A$10.4 Million

Clinuvel Pharmaceuticals Ltd - Hy Revenues a$36.9 Mln

THOMSON REUTERS

Exploring 3 High Growth Tech Stocks in Australia

Simply Wall St.

Clinuvel Pharmaceuticals Anticipates Health Canada Marketing Authorization Decision For Vitiligo Treatment Candidate in H2

MT Newswires Live

ASX Growth Companies With High Insider Ownership January 2026

Simply Wall St.

Does Clinuvel’s New VLRX-L Injectable Platform Shift the Long-Term Pipeline Narrative for ASX:CUV?

Simply Wall St.

Clinuvel Pharmaceuticals (ASX:CUV) Valuation Check As VLRX L Preclinical Milestone Expands Pipeline Potential

Simply Wall St.

Clinuvel Pharmaceuticals Starts Dosing in Preclinical Study With Controlled-Release Injectable Platform Candidate

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CUV.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CUV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","market":"AU","secType":"STK","nameCN":"CLINUVEL PHARMACEUTICALS LTD","latestPrice":9.6,"timestamp":1773964876112,"preClose":9.47,"halted":0,"volume":36901,"delay":0,"changeRate":0.013727560718056916,"nameEN":"CLINUVEL PHARMACEUTICALS LTD","floatShares":41318955,"shares":50200740,"eps":0.643659,"marketStatus":"Trading","change":0.13,"latestTime":"03-20 11:04:39 AEDT","open":9.66,"high":9.9,"low":9.42,"amount":354578,"amplitude":0.050686,"askPrice":9.61,"askSize":23,"bidPrice":9.58,"bidSize":50,"shortable":3,"etf":0,"ttmEps":0.643659,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773982800000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":9.47,"dividendRate":0.005208,"openAndCloseTimeList":[[1773961200000,1773982800000]],"volumeRatio":2.754399,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CUV.AU","preClose":9.47,"auctionPrice":9.66,"auctionVolume":106,"auctionTime":1773961156609,"referenceTime":1773912604089,"auction":1,"marketStatus":"盘前竞价","timestamp":1773961156609}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","floatShares":41318955,"roa":"10.62%","roe":"13.96%","lyrEps":0.717999,"volumeRatio":2.754399,"shares":50200740,"dividePrice":0.05,"high":9.9,"amplitude":0.050686,"preClose":9.47,"low":9.42,"week52Low":9.31,"pbRate":"1.94","psRate":"5.00","week52High":13.933,"institutionHeld":0,"latestPrice":9.6,"committee":0.369863,"eps":0.643659,"divideRate":0.005208,"volume":36901,"delay":0,"ttmEps":0.643659,"open":9.66,"prevYearClose":12.46,"prevWeekClose":9.93,"prevMonthClose":10.01,"prevQuarterClose":12.46,"fiveDayClose":9.93,"twentyDayClose":11.67,"sixtyDayClose":12.78,"dividendPayoutRate":0.06921842705277628,"dividendFrequency":"A","dividendGrowthYears":5,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.0025824359172833843},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUV.AU\",params:#limit:5,,,undefined,":[{"date":"2026-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772060400000,"name":null,"time":"","dateTimestamp":1772024400000,"actualEps":null},{"date":"2025-09-04","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-05","defaultRemindTime":1756944000000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-05","currency":"AUD","dateTimestamp":1756908000000,"payDate":"2025-09-19"},{"date":"2025-08-28","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756339200000,"name":null,"time":"","dateTimestamp":1756303200000,"actualEps":null},{"date":"2025-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-09-05","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-09-06","defaultRemindTime":1725494400000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-20","payableDate":"2024-09-06","currency":"AUD","dateTimestamp":1725458400000,"payDate":"2024-09-20"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUV.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-03","recordDate":"2020-09-04","paymentDate":"2020-09-18","value":0.025,"currency":"AUD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-17","value":0.025,"currency":"AUD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-09-21","value":0.04,"currency":"AUD"},{"executeDate":"2023-09-05","recordDate":"2023-09-06","paymentDate":"2023-09-20","value":0.05,"currency":"AUD"},{"executeDate":"2024-09-05","recordDate":"2024-09-06","paymentDate":"2024-09-20","value":0.05,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CUV.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620277043","title":"ASX 300 healthcare stock outperforming today on 'strategic' leadership news","url":"https://stock-news.laohu8.com/highlight/detail?id=2620277043","media":"MotleyFool","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620277043?lang=en_us&edition=fundamental","pubTime":"2026-03-20 08:00","pubTimestamp":1773964847,"startTime":"0","endTime":"0","summary":"Over the past 12 months, shares in the ASX 300 healthcare stock have slumped 20% Addressing that decline, Rosenfeld said, \"Market data tell a clear story: pre-revenue biotechs often outperform as perception and hope dominates investment decisions, while profitable companies executing quietly can be undervalued.\" He added: The board, market analysts, and sophisticated institutions recognise that our share price does not reflect the company's performance. It reflects a perceived ceiling on further growth. Our job, and Philippe's, is to break through that ceiling.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/20/asx-300-healthcare-stock-outperforming-today-on-strategic-leadership-news/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/20/asx-300-healthcare-stock-outperforming-today-on-strategic-leadership-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","CUV.AU","XKO.AU","BK7508"],"gpt_icon":0},{"id":"2620277689","title":"Clinuvel Pharmaceuticals Retains Philippe Wolgen as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2620277689","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620277689?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:29","pubTimestamp":1773962952,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  confirmed that Philippe Wolgen will remain chief executive, citing his scientific expertise, regulatory experience, and steady leadership as vital for guiding the company through its key growth phase, according to a Friday Australian bourse filing.The company's shares were up 1% in recent Friday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2620927483","title":"Clinuvel Pharmaceuticals Ltd-Chair Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2620927483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620927483?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:30","pubTimestamp":1773955855,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUE9D6FZ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2620274866","title":"Clinuvel Pharmaceuticals  - We Expect That Nasdaq Listing for a Level Ii Adr May Be Possible in the First Half of This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2620274866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620274866?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:30","pubTimestamp":1773955855,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUE9D6FZ6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2620027485","title":"Clinuvel Pharmaceuticals Ltd - Philippe Wolgen to Continue as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2620027485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620027485?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:30","pubTimestamp":1773955855,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUE9D6FZ6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CUV.AU","BK7067"],"gpt_icon":0},{"id":"2620027294","title":"Morgans says these small-cap ASX shares could rise 30% to 80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620027294","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620027294?lang=en_us&edition=fundamental","pubTime":"2026-03-18 08:57","pubTimestamp":1773795437,"startTime":"0","endTime":"0","summary":"Having some exposure to the small side of the market can be a good thing for a balanced portfolio, if your risk tolerance allows for it.After all, the potential returns from small-cap ASX shares can be significantly greater than those on offer with large caps.With that in mind, here are two small-cap shares that Morgans thinks could rise strongly from current levels. Let's see what it is recommending:. This biopharmaceuticals company disappointed Morgans during the first half, with softer-than-expected revenue growth and higher-than-expected cost growth.However, the broker remains positive, especially given that this small-cap ASX share trades on lower-than-normal multiples.As a result, the broker has put a speculative buy rating and $13.00 price target on its shares. This implies potential upside of 30% for investors from current levels. It said:. Whilst we downgrade our FY26-17 EBITDA forecasts by 10-20% reflecting revised guidance, given RDY's robust pipeline, potential catalysts , ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/morgans-says-these-small-cap-asx-shares-could-rise-30-to-80/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/18/morgans-says-these-small-cap-asx-shares-could-rise-30-to-80/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7016","CUV.AU","BK7508","RDY.AU"],"gpt_icon":0},{"id":"2618647249","title":"A Look At Clinuvel Pharmaceuticals (ASX:CUV) Valuation After Softer Half Year Earnings Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647249","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647249?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:20","pubTimestamp":1773015634,"startTime":"0","endTime":"0","summary":"Why Clinuvel’s latest half year result has caught investor attention\nClinuvel Pharmaceuticals (ASX:CUV) has drawn fresh interest after reporting half year earnings to 31 December 2025, with revenue of A$40.56 million and net income of A$10.44 million, both below the prior period.\nSee our latest analysis for Clinuvel Pharmaceuticals.\nAt a share price of A$10.16, Clinuvel’s recent half year result lands against a backdrop of weaker momentum, with a 30 day share price return of 8.14% and a 90...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/a-look-at-clinuvel-pharmaceuticals-asxcuv-valuation-after-so","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/a-look-at-clinuvel-pharmaceuticals-asxcuv-valuation-after-so","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CUV.AU"],"gpt_icon":0},{"id":"2617599594","title":"Clinuvel Pharmaceuticals announces investor webinar release for the six months ended 31 December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2617599594","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617599594?lang=en_us&edition=fundamental","pubTime":"2026-03-05 10:48","pubTimestamp":1772678913,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals Limited announced the availability of an investor and analyst webinar  discussing its financial results for the six months ended 31 December 2025, hosted at 18:00 AEDT on 26 February 2026, posted at CLINUVEL news website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL7ks45p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CUV.AU","BK7067"],"gpt_icon":0},{"id":"2616804550","title":"Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2616804550","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616804550?lang=en_us&edition=fundamental","pubTime":"2026-03-02 12:27","pubTimestamp":1772425659,"startTime":"0","endTime":"0","summary":"An organic growth in Australian healthcare services is likely due to improving availability of bulk-billing general practitioners, offset by ongoing wage pressures, Jefferies said in a Monday report.I","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MPL.AU","BK7096","XAO.AU","CSL.AU","REG.AU","BK4581","TLX.AU","SHL.AU","NHF.AU","RHC.AU","BK7511","BK7067","XKO.AU","BK7508","BK7501","HLS.AU","XJO.AU","BK4588","LABU","NEU.AU","BK7103","COH.AU","BK7113","CUV.AU","FPH.AU","IDX.AU","SIG.AU","HCAR","CU6.AU","BK4585","BK7007","XLV","ANN.AU","BK7089","BK7124","IMM.AU","BK7509","MVF.AU","BK7126","XBI","MSB.AU"],"gpt_icon":0},{"id":"2616447918","title":"Assessing Clinuvel Pharmaceuticals (ASX:CUV) Valuation After EMA SCENESSE Approval And Half Year Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2616447918","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616447918?lang=en_us&edition=fundamental","pubTime":"2026-03-01 04:29","pubTimestamp":1772310599,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) is in focus after a key European Medicines Agency approval for year round SCENESSE use in erythropoietic protoporphyria, alongside fresh half year earnings that show revenue of A$40.56 million and net income of A$10.44 million.\nSee our latest analysis for Clinuvel Pharmaceuticals.\nEven with the EMA approval and fresh half year numbers, sentiment around Clinuvel looks cautious. A 1 day share price return of 9.33% decline and a year to date share price return...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/assessing-clinuvel-pharmaceuticals-asxcuv-valuation-after-em","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/assessing-clinuvel-pharmaceuticals-asxcuv-valuation-after-em","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EMA","CUV.AU"],"gpt_icon":0},{"id":"2614288815","title":"BUZZ-Australia's Clinuvel Pharma at near 9-month low; Jefferies trims PT on slower sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2614288815","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614288815?lang=en_us&edition=fundamental","pubTime":"2026-02-27 12:54","pubTimestamp":1772168074,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Clinuvel Pharma at near 9-month low; Jefferies trims PT on slower sales** Shares of drug maker Clinuvel Pharmaceuticals CUV.AX slip as much as 8.24% to A$10.130, lowest since July 8, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL6N3ZN0AD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2614205062","title":"Clinuvel H1 net profit after tax AUD 10.4 million -26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614205062","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614205062?lang=en_us&edition=fundamental","pubTime":"2026-02-26 11:04","pubTimestamp":1772075090,"startTime":"0","endTime":"0","summary":"Clinuvel reported record December-half sales revenues of AUD 36.9 million in the six months to 31 December 2025 (+4%), with total revenue of AUD 40.6 million. Expenses rose to AUD 26.0 million , and net profit after tax fell to AUD 10.4 million , with basic earnings per share of AUD 0.21 . Cash and term deposits increased to AUD 233.0 million (+4%), and the balance sheet remained free of external borrowings. The company said higher spending reflected expansion plans and increased R&D activity, with personnel costs up 16% and clinical and non-clinical development costs up 19%. Commercial distribution expenses rose 42%, and finance and legal expenses increased 47%, primarily linked to an application to the U.S. SEC to upgrade its Level I ADRs to Level II for a NASDAQ listing. Management also highlighted preparation for larger markets in vitiligo and first entry to market for NEURACTHEL, an ACTH analogue.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL1H6Ww2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"gpt_icon":0},{"id":"2614069376","title":"BRIEF-Clinuvel Pharmaceuticals Posts HY Net Profit After Tax A$10.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614069376","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614069376?lang=en_us&edition=fundamental","pubTime":"2026-02-26 09:23","pubTimestamp":1772068995,"startTime":"0","endTime":"0","summary":"BRIEF-Clinuvel Pharmaceuticals Posts HY Net Profit After Tax A$10.4 MillionFeb 26 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX:HY  NET PROFIT AFTER TAX A$10.4 MILLIONHY  REVENUES A$36.9 MILLIONFurther company coverage: CUV.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZL25Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2614050890","title":"Clinuvel Pharmaceuticals Ltd - Hy  Revenues a$36.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614050890","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614050890?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:56","pubTimestamp":1772060177,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL25Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2608307388","title":"Exploring 3 High Growth Tech Stocks in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2608307388","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608307388?lang=en_us&edition=fundamental","pubTime":"2026-02-04 03:06","pubTimestamp":1770145565,"startTime":"0","endTime":"0","summary":"The Australian stock market is experiencing a potential rebound, with shares expected to rise by over 1% following recent sell-offs, as investors anticipate the Reserve Bank of Australia's impending interest rate hike decision. In this dynamic environment, high-growth tech stocks can offer intriguing opportunities for investors seeking innovation and resilience amidst economic shifts and evolving global strategies.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/exploring-3-high-growth-tech-stocks-in-australia-11","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/exploring-3-high-growth-tech-stocks-in-australia-11","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","XAO.AU","XKO.AU","CUV.AU","BK7067","XJO.AU","BK7094","CGS.AU","PYC.AU"],"gpt_icon":0},{"id":"2608839722","title":"Clinuvel Pharmaceuticals Anticipates Health Canada Marketing Authorization Decision For Vitiligo Treatment Candidate in H2","url":"https://stock-news.laohu8.com/highlight/detail?id=2608839722","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608839722?lang=en_us&edition=fundamental","pubTime":"2026-02-02 11:47","pubTimestamp":1770004022,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  anticipates the receipt of Health Canada's marketing authorization decision for its drug candidate Scenesse for the treatment of vitiligo in the second half of 2026, according to a Monday Australian bourse filing.The company also expects to report top-line preclinical results from its controlled-release liquid injectable platform candidate, VLRX-L, study in the first half, the filing said.The company's shares shed about 1% in recent Monday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2607545890","title":"ASX Growth Companies With High Insider Ownership January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2607545890","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607545890?lang=en_us&edition=fundamental","pubTime":"2026-01-30 03:09","pubTimestamp":1769713763,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a period of uncertainty with flat trading and cautious investor sentiment following the U.S. Federal Reserve's recent decision to hold interest rates steady, attention turns to how local indices will respond to upcoming announcements from the Reserve Bank of Australia. In this environment, growth companies with high insider ownership can be particularly appealing, as they often signal strong confidence from those who know the business best and may offer...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-high-insider-ownership-january-202-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-high-insider-ownership-january-202-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EIQ.AU","BK7113","P1E.AU","BK7142","BK7095","3DP.AU","WZR.AU","BK7116","NWF.AU","XJO.AU","REG.AU","BK7117","BK7017","AEM.AU","BK7036","SKS.AU","BK7506","BK7067","LM8.AU","XKO.AU","BK7508","XAO.AU","AV1.AU","TTT.AU","CUV.AU","BK7093","SEA.AU","BK7016","BK7023"],"gpt_icon":0},{"id":"2604744915","title":"Does Clinuvel’s New VLRX-L Injectable Platform Shift the Long-Term Pipeline Narrative for ASX:CUV?","url":"https://stock-news.laohu8.com/highlight/detail?id=2604744915","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604744915?lang=en_us&edition=fundamental","pubTime":"2026-01-17 01:30","pubTimestamp":1768584634,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals has recently begun dosing in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform, marking the first formal evaluation of this next-generation delivery technology.\nThis step signals an effort to build a broader pipeline based on in-house intellectual property that could diversify the business beyond its existing treatment franchise if development progresses successfully.\nWe’ll now explore how advancing the proprietary VLRX-L...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/does-clinuvels-new-vlrx-l-injectable-platform-shift-the-long","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/does-clinuvels-new-vlrx-l-injectable-platform-shift-the-long","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VLRX","CUV.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2603545606","title":"Clinuvel Pharmaceuticals (ASX:CUV) Valuation Check As VLRX L Preclinical Milestone Expands Pipeline Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2603545606","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603545606?lang=en_us&edition=fundamental","pubTime":"2026-01-15 15:34","pubTimestamp":1768462462,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) has started dosing patients in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform. This marks its first next-generation delivery technology to enter formal preclinical testing.\nSee our latest analysis for Clinuvel Pharmaceuticals.\nThe VLRX-L preclinical milestone comes as the share price sits at A$12.75, with a 1-day share price return of 4.25% and a 90-day share price return of 10.29%, while the 1-year total shareholder...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-as-vlrx-l-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-as-vlrx-l-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CUV.AU","BK7508","BK7067","VLRX"],"gpt_icon":0},{"id":"2602810564","title":"Clinuvel Pharmaceuticals Starts Dosing in Preclinical Study With Controlled-Release Injectable Platform Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2602810564","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602810564?lang=en_us&edition=fundamental","pubTime":"2026-01-12 10:08","pubTimestamp":1768183730,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  started dosing in its preclinical study with its controlled-release liquid injectable platform candidate, VLRX-L, designed to control the release of peptides, according to a Monday Australian bourse filing.The study seeks to evaluate the controlled-release profile of VLRX-L candidates and determine the reproducibility of drug release using an in-vitro model, the filing said.The company seeks to complete the preclinical program in the second half of 2026.Clinuvel Pharmaceuticals' shares rose almost 2% in recent trading on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","CUV.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":48,"code":"91000000","status":"200"}]}}